Search Result

Results for "

homozygous

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ANGPTL (1) Apolipoprotein (2) ATM/ATR (1) CFTR (3) DNA/RNA Synthesis (1) Fluorescent Dye (1) G-quadruplex (1) GABA Receptor (1) HCV (2) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) PROTACs (1) Radionuclide-Drug Conjugates (RDCs) (1) Ras (1) Reference Standards (1) STAT (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Infection (1) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15448

Tezacaftor Maximum Cited Publications 25 Publications Verification VX-661	CFTR	Cancer
Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-108764

Mipomersen sodium 2 Publications Verification ISIS 301012	Apolipoprotein HCV	Metabolic Disease
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-137516

LC-2 2 Publications Verification	PROTACs Ras	Cancer
LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC₅₀s between 0.25 and 0.76 μM . LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines .

HY-P99194

Evinacumab 1 Publications Verification REGN1500	ANGPTL	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

HY-148647

Mipomersen 2 Publications Verification ISIS 301012 free base	Apolipoprotein HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-136835

GJ071 oxalate	ATM/ATR	Neurological Disease
GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons .

HY-15448R

Tezacaftor (Standard) VX-661 (Standard)	CFTR Reference Standards	Cancer
Tezacaftor (Standard) is the analytical standard of Tezacaftor. This product is intended for research and analytical applications. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-15448S1

Tezacaftor-d6 VX-661-d₆	Isotope-Labeled Compounds CFTR	Cancer
Tezacaftor-d₆ (VX-661-d₆) is deuterium labeled Tezacaftor. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

HY-131885

RuBi-Glutamate hexafluorophosphate sodium	GABA Receptor	Neurological Disease
RuBi-Glutamate hexafluorophosphate sodium is a neuronal activator. RuBi-Glutamate hexafluorophosphate sodium photocleaves to release glutamate upon one- or two-photon excitation, activating glutamate receptors in cortical pyramidal neurons. RuBi-Glutamate hexafluorophosphate sodium reduces peak amplitude of evoked GABAergic inhibitory postsynaptic currents in its caged form. RuBi-Glutamate hexafluorophosphate sodium can be used for the research of Huntington's disease .

HY-D3310

Fluorescein-12-dGTP	Fluorescent Dye	Others
Fluorescein-12-dGTP is a fluorescein-labeled deoxyguanosine triphosphate. Fluorescein-12-dGTP incorporates into complementary allele-specific primers at SNP sites, enabling FRET with cationic conjugated polymer PFP via DNA-PFP electrostatic interactions. Fluorescein-12-dGTP incorporates into G-allele-specific primers for homozygous G/G SNP genotypes to enable genotype discrimination. Fluorescein-12-dGTP serves as a fluorescently labeled nucleotide for homogeneous solution-based SNP and FRET genotyping assays (Ex/Em = 498/517 nm) .

HY-P11486

NOTA-RHAU18	Radionuclide-Drug Conjugates (RDCs) G-quadruplex DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [ ¹⁸F]AlF-NOTA-RHAU18. [ ¹⁸F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [ ¹⁸F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [ ¹⁸F]AlF-NOTA-RHAU18 can also be used in PET imaging studies .

HY-P991888

INCA033989	STAT	Cardiovascular Disease Cancer
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (K_D = 1.75 nM for mutCALR ^del52; K_D = 6.78 nM for mutCALR ^ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .

Cat. No.	Product Name	Type

HY-D3310

Fluorescein-12-dGTP	Fluorescent Dyes
Fluorescein-12-dGTP is a fluorescein-labeled deoxyguanosine triphosphate. Fluorescein-12-dGTP incorporates into complementary allele-specific primers at SNP sites, enabling FRET with cationic conjugated polymer PFP via DNA-PFP electrostatic interactions. Fluorescein-12-dGTP incorporates into G-allele-specific primers for homozygous G/G SNP genotypes to enable genotype discrimination. Fluorescein-12-dGTP serves as a fluorescently labeled nucleotide for homogeneous solution-based SNP and FRET genotyping assays (Ex/Em = 498/517 nm) .

Fluorescein-12-dGTP

Fluorescent Dyes

Fluorescein-12-dGTP is a fluorescein-labeled deoxyguanosine triphosphate. Fluorescein-12-dGTP incorporates into complementary allele-specific primers at SNP sites, enabling FRET with cationic conjugated polymer PFP via DNA-PFP electrostatic interactions. Fluorescein-12-dGTP incorporates into G-allele-specific primers for homozygous G/G SNP genotypes to enable genotype discrimination. Fluorescein-12-dGTP serves as a fluorescently labeled nucleotide for homogeneous solution-based SNP and FRET genotyping assays (Ex/Em = 498/517 nm) .

Cat. No.	Product Name	Target	Research Area

HY-P11486

NOTA-RHAU18	Radionuclide-Drug Conjugates (RDCs) G-quadruplex DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [ ¹⁸F]AlF-NOTA-RHAU18. [ ¹⁸F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [ ¹⁸F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [ ¹⁸F]AlF-NOTA-RHAU18 can also be used in PET imaging studies .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99194

Evinacumab 1 Publications Verification REGN1500	ANGPTL	Cardiovascular Disease Metabolic Disease
Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia .

HY-P991888

INCA033989	STAT	Cardiovascular Disease Cancer
INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (K_D = 1.75 nM for mutCALR ^del52; K_D = 6.78 nM for mutCALR ^ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .

Cat. No.	Product Name	Chemical Structure

HY-15448S1

Tezacaftor-d6
Tezacaftor-d₆ (VX-661-d₆) is deuterium labeled Tezacaftor. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

Tezacaftor-d6

Tezacaftor-d₆ (VX-661-d₆) is deuterium labeled Tezacaftor. Tezacaftor (VX-661) is a F508del CFTR corrector. It helps CFTR protein reach the cell surface. However, Ivacaftor (VX-770, HY-13017), a CFTR potentiator, helps to prolong the opening time of cell surface CFTR protein channels. Tezacaftor combining with Ivacaftor, shows potent efficacy against cystic fibrosis and diseases with homozygous for the CFTR Phe508del mutation. Moreover, Elexacaftor (VX-445, HY-111772) is also a CFTR corrector. Elexacaftor-Tezacaftor-Ivacaftor aims at with cystic fibrosis (CF) with at least one Phe508del mutation, often avoids the indication for lung transplantation .

Cat. No.	Product Name		Classification

HY-108764

Mipomersen sodium 2 Publications Verification ISIS 301012		Antisense Oligonucleotides
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-148647

Mipomersen 2 Publications Verification ISIS 301012 free base		Antisense Oligonucleotides
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.